Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics Sep 11, 2023 07:00AM
Immatics (IMTX) Announces $35 Million Equity Investment from Bristol Myers Squibb (BMY) Jul 24, 2023 07:13AM
Immatics (IMTX) Reports Interim Clinical Data from Ongoing Phase 1b trial of ACTengine IMA203 TCR-T May 2, 2023 07:01AM
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME May 2, 2023 07:00AM
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration May 1, 2023 07:00AM


Mar 21, 2023 07:33AM Immatics (IMTX) Reports FY22 Results, Issues Corporate Update
Mar 21, 2023 07:31AM Immatics Announces Full Year 2022 Financial Results and Corporate Update
Nov 17, 2022 07:00AM Immatics Announces Third Quarter 2022 Financial Results and Business Update
Oct 10, 2022 07:36AM Immatics (IMTX) Reports Interim Clinical Data Update on ACTengine IMA203 TCR-T Monotherapy Targeting PRAME
Oct 10, 2022 07:36AM Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
Sep 10, 2022 03:06AM Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
Aug 23, 2022 07:00AM Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME
Aug 9, 2022 07:00AM Immatics Announces Second Quarter 2022 Financial Results and Business Update
Jul 27, 2022 06:59AM Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
Jun 2, 2022 07:07AM Immatics (IMTX) Reports Q1 Revenue of $114.2M, Net Income of $95.1M
Jun 2, 2022 07:05AM Immatics Announces First Quarter 2022 Financial Results and Business Update
Jun 2, 2022 06:59AM Immatics (IMTX) and Bristol Myers Squibb (BMY) Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
Jun 2, 2022 06:59AM Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
Jun 2, 2022 06:59AM Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
May 18, 2022 07:00AM Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors
May 10, 2022 07:00AM Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
Mar 23, 2022 07:00AM Immatics Announces Full Year 2021 Financial Results and Corporate Update
Feb 4, 2022 06:59AM Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
Dec 14, 2021 07:00AM Immatics (IMTX), Bristol Myers Squibb (BMY) Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
Dec 14, 2021 06:59AM Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
Dec 14, 2021 06:59AM Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
Nov 16, 2021 07:00AM Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update
Nov 9, 2021 08:00AM Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME
Nov 1, 2021 08:00AM Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer’s 36th Annual Meeting
Aug 10, 2021 07:00AM Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update
Jun 29, 2021 08:30AM Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND
May 26, 2021 07:08AM Immatics (IMTX) Announces Changes to its Board of Directors
May 26, 2021 07:00AM Immatics Announces Changes to its Board of Directors
May 18, 2021 07:00AM Immatics Announces First Quarter 2021 Financial Results and Business Update
May 11, 2021 07:00AM Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME
Mar 30, 2021 07:00AM Immatics Announces Full Year 2020 Financial Results and Corporate Update
Mar 17, 2021 07:00AM Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs
Dec 2, 2020 07:00AM Immatics Announces Third Quarter 2020 Financial Results and Business Update
Nov 10, 2020 07:00AM Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
Oct 29, 2020 07:00AM Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8
Sep 29, 2020 07:07AM Immatics (IMTX) Announces Arnd Christ as CFO
Sep 29, 2020 07:00AM Immatics Appoints Arnd Christ as Chief Financial Officer
Sep 15, 2020 07:00AM Immatics Appoints Biotech Executive Eliot Forster to Board of Directors
Sep 10, 2020 07:07AM Immatics (IMTX) Provides Update on IMA204 ACTengine Cell Therapy Program Targeting the Tumor Microenvironment
Sep 10, 2020 07:00AM Immatics Provides Update on IMA204 ACTengine® Cell Therapy Program Targeting the Tumor Microenvironment
Sep 3, 2020 07:00AM Immatics Announces Second Quarter 2020 Financial Results and Business Update
Aug 18, 2020 07:00AM Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs
Aug 6, 2020 07:00AM Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth
Jul 9, 2020 07:00AM Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ
Jul 2, 2020 07:00AM Immatics Announces Completion of Business Combination and Listing on NASDAQ